1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Healthcare Consultants - General Discussion

Anonymous general discussion board for healthcare consultants

Sort By:
Title
Replies Views ↓
Last Message
  1. Anonymous
    Replies:
    21
    Views:
    11,659
  2. Anonymous
    Replies:
    12
    Views:
    4,641
  3. Anonymous
    Replies:
    1
    Views:
    3,555
  4. anonymous
    Replies:
    1
    Views:
    1,441
  5. anonymous
    Replies:
    0
    Views:
    1,263
  6. anonymous
    Replies:
    1
    Views:
    1,237
  7. anonymous
    Replies:
    0
    Views:
    1,213
  8. anonymous
    Replies:
    3
    Views:
    1,033
  9. Gella
    Replies:
    0
    Views:
    946

Thread Display Options

Loading...